Project Grant R21AR088461
Award Date 8/17/26
Completion Date 7/31/28
Dollars Obligated $374K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Wisconsin System $164,000 on December 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund research into the role of the protein SKNAC in mechanically induced skeletal muscle growth. The research investigates signaling pathways that promote muscle mass preservation and growth in response to mechanical loading....
- The National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Texas A&M University System Health Science Center $114,073 on September 23, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds investigation of sympathetic signaling as a mechanism underlying bone loss following spinal cord injury. The research comprises two aims: determining spinal-cord-injury-level-dependent effects of...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Health Science Center at San Antonio $496,963 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the osteocyte interactome's role in bone mechanotransduction and osteogenesis. The research elucidates how osteocytes—the primary mechanosensory cells in bone—coordinate bone remodeling through a...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Trustees of Columbia University in the City of New York $100,228 on November 27, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research investigates the mechanotransduction pathways regulating tendon development, specifically the role of MRTF/SRF signaling in response to mechanical cues. The project integrates in vitro models using mouse embryonic stem...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Southwestern Medical Center $613,036 on August 1, 2026, for investigator-initiated research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, "Leveraging Lymphatics to Reverse Heterotopic Ossification," addresses the pathologic formation of extra-skeletal bone occurring in approximately twenty percent of patients following hip...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health under the Department of Health and Human Services, awarded $585,012 to Massachusetts General Hospital on June 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research investigating the role of the C10ORF10/DEPP1 protein in skeletal muscle atrophy. The recipient will conduct three specific aims: defining the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor College of Medicine $679,931 on April 20, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates how SPEG kinase regulates calcium leak from the sarcoplasmic reticulum via phosphorylation of the RYR1 calcium release channel at serine 2902, with direct application to understanding and treating congenital myopathies and malignant hyperthermia...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Boston Children's Hospital a $177,000 Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) on August 20, 2025, with completion anticipated by July 31, 2027. The project delivers research services focused on identifying novel modulators of limb development and chondrocyte maturation through genome-wide functional screening. The research team will...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor University $503,834 on August 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate whether pharmacologic activation of satellite cells can prevent chemotherapy-induced delays in skeletal muscle growth and development in pediatric cancer patients. The research addresses the understudied adverse effects of CHOP chemotherapy (cyclophosphamide,...